-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Jasper Therapeutics, Maintains $40 Price Target

Benzinga·03/11/2025 17:05:13
Listen to the news
HC Wainwright & Co. analyst Emily Bodnar reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Buy and maintains $40 price target.